Prescribing Patterns of Intravenous Golimumab for Rheumatoid Arthritis

Clinical Therapeutics

Volumn 37, Issue 9, 2015, Pages 2028-2036

  Brady, Brenna L ^a   Tkacz, Joseph P ^a   Lofland, Jennifer ^b   Meyer, Roxanne ^b   Bolge, Susan C ^b  

^a Health Analytics LLC   (United States)

^b Janssen Scientific Affairs ^*  (Australia)

Author keywords

anti TNF; biologic; chart review; intravenous golimumab; rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; DEPRESSION; DIABETES MELLITUS; DRUG UTILIZATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MUSCULOSKELETAL DISEASE; PRESCRIPTION; RHEUMATOID ARTHRITIS; UNITED STATES; AGED; ARTHRITIS, RHEUMATOID; CLINICAL PRACTICE; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHOTREXATE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; UNITED STATES;

EID: 84941191553     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.06.017     Document Type: Article

References (33)

1. A. Gibofsky Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis The American journal of managed care 18 Suppl 2012 S295 S302
2. D.L. Scott Biologics-based therapy for the treatment of rheumatoid arthritis Clinical pharmacology and therapeutics 91 2012 30 43
3. P.C. Taylor, and M. Feldmann Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis Nature reviews. Rheumatology 5 2009 578 582
4. R. Greenapple Trends in biologic therapies for rheumatoid arthritis: results from a survey of payers and providers American health & drug benefits 5 2012 83 92
5. M. Jani, A. Barton, R.B. Warren, and et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases Rheumatology (Oxford) 53 2014 213 222
6. S. Lloyd, S. Bujkiewicz, A.J. Wailoo, and et al. The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis Rheumatology (Oxford) 49 2010 2313 2321
7. R. Rendas-Baum, G.V. Wallenstein, T. Koncz, and et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-alpha inhibitors Arthritis research & therapy 13 2011 R25
8. Remicade (infliximab) Prescribing Information 2013 Janssen Biotech Inc Horsham, PA
9. Humira (adalimumab) Prescribing Information 2014 AbbVie Inc North Chicago, IL
10. Enbrel (etanercept) Prescribing Information 2013 Amgen Inc Thousand Oaks, CA
11. Cimzia (certolizumab pegol) Prescribing Information 2010 UCB Inc Smyrna, GA
12. Simponi (golimumab) Prescribing Information 2014 Janssen Biotech Inc Horsham, PA
13. Simponi Aria (golimumab) Prescribing Information 2014 Janssen Biotech Inc Horsham, PA
14. Orencia (abatacept) Prescribing Information 2013 Bristol-Myers Squibb Company Princeton, NJ
15. Actemra (tocilizumab) Prescribing Information 2014 Genentech Inc South San Francisco, CA
16. Kineret (anakinra) Prescribing Information 2013 Swedish Orphan Biovitrum AB Stockholm, Sweden
17. Rituxan (rituximab) Prescribing Information 2010 Genentech Inc South San Francisco, CA
18. H. Canhao, A.M. Rodrigues, A.F. Mourao, and et al. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis Rheumatology (Oxford) 51 2012 2020 2026
19. M.C. Genovese, A. Covarrubias, G. Leon, and et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate Arthritis and rheumatism 63 2011 2854 2864
20. T.K. Huynh, A. Ostergaard, C. Egsmose, and O.R. Madsen Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis Patient preference and adherence 8 2014 93 99
21. P. Moreau, H. Pylypenko, S. Grosicki, and et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study The Lancet. Oncology 12 2011 431 440
22. S. Schwartzman, and G.J. Morgan Jr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis research & therapy 6 Suppl 2 2004 S19 S23
23. G.E. Umpierrez, K. Latif, J. Stoever, and et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis The American journal of medicine 117 2004 291 296
24. J.L. Barton Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy Patient preference and adherence 3 2009 335 344
25. Food and Drug Administration. Highlights of Prescribing Information - Simponi Aria. 2014; http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125433s005lbl.pdf.
26. J.R. Curtis, J.W. Baddley, S. Yang, and et al. Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis Arthritis research & therapy 13 2011 R155
27. J. Zhang, F. Xie, E. Delzell, and et al. Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US Medicare program Arthritis care & research 65 2013 1743 1751
28. J. Tkacz, L. Ellis, S.C. Bolge, and et al. Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients Clinical therapeutics 36 2014 737 747
29. M. Dougados, M. Soubrier, A. Antunez, and et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA) Ann Rheum Dis 73 2014 62 68
30. S.E. Gabriel, and K. Michaud Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases Arthritis research & therapy 11 2009 229
31. J.R. Curtis, and J.A. Singh Use of biologics in rheumatoid arthritis: current and emerging paradigms of care Clinical therapeutics 33 2011 679 707
32. F. Chilton, and R.A. Collett Treatment choices, preferences and decision-making by patients with rheumatoid arthritis Musculoskeletal care 6 2008 1 14
33. Y. Yazici, N. Shi, and A. John Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy Bulletin of the NYU hospital for joint diseases 66 2008 77 85